Summary: In this article, Catalent expert, Victor Vinci was asked to respond and give his insight into manufacturing platforms and how they will help drugmakers meet demands.

Summary: In this article, Catalent expert George Buchman discusses the recent increase in gene therapy approvals & how we can accelerate the manufacturing speed with platform processes.

In this episode of “The Top Line”, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. The conversation covers cell collection, the critical first step in advanced therapy manufacturing.

Summary: Learn about the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

Summary: Learn about the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

Here we present an in-line cell lysis assembly developed at Catalent to increase throughput while controlling critical parameters such as time of contact and solutions ratio, delivering a high-quality product.

Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.

In this article, Catalent's experts detail a scalable approach to fast-tracking AAVs with integrated solutions, from clonal cell-lines to market.

Catalent's UpTempo AAV platform process offers clients accelerated timelines for producing their clinical materials. The scalable, CGMP-ready platform process can significantly reduce the time from gene to clinic through a simplified supply chain.

Catalent experts discuss UpTempo℠ AAV, a one-stop integrated viral vector platform for speed to clinic. Discover how implementing the right process, utilizing a clonal HEK293 cell line, and leveraging a range of off-the-shelf plasmids, along with qualified analytical methods, can support a robust supply chain for the development and manufacture of AAV vectors.